A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells.
Dipeptidyl peptidase IV (DPPIV) is a cell surface peptidase expressed by normal melanocytes, epithelial cells, and other cells. Malignant cells, including melanomas and carcinomas, frequently lose or alter DPPIV cell surface expression. Loss of DPPIV expression occurs during melanoma progression at a stage where transformed melanocytes become independent of exogenous growth factors for survival. Tetracycline-inducible expression vectors were constructed to express DPPIV in human melanoma cells. Reexpressing DPPIV in melanoma cells at or below levels expressed by normal melanocytes induced a profound change in phenotype that was characteristic of normal melanocytes. DPPIV expression led to a loss of tumorigenicity, anchorage-independent growth, a reversal in a block in differentiation, and an acquired dependence on exogenous growth factors for cell survival. Suppression of tumorigenicity and reversal of a block in differentiation were dependent on serine protease activity, assessed using mutant DPPIV molecules containing serine-->alanine substitutions. Surprisingly, dependence on exogenous growth factors was not dependent on serine protease activity. Reexpression of either wild-type or mutant DPPIV rescued expression of a second putative cell surface serine peptidase, fibroblast activation protein alpha, which can form a heterodimer with DPPIV. This observation suggests that rescue of fibroblast activation protein alpha may play a role in regulating growth of melanocytic cells. These results support the view that downregulation of DPPIV is an important early event in the pathogenesis of melanoma.
Wesley
U V
UV
Memorial Sloan-Kettering Cancer Center, Weill Graduate School of Medical Sciences of Cornell University, New York 10021, USA.
Albino
A P
AP
Tiwari
S
S
Houghton
A N
AN
D017209:Apoptosis / Q000276:immunology; D002453:Cell Cycle / Q000276:immunology; D002455:Cell Division / Q000276:immunology; D017077:Culture Media, Conditioned; D018819:Dipeptidyl Peptidase 4 / Q000096:biosynthesis / Q000502:physiology*; D010450:Endopeptidases; D018093:Gelatinases; D006131:Growth Inhibitors / Q000096:biosynthesis / Q000502:physiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008544:Melanocytes / Q000201:enzymology* / Q000276:immunology / Q000473:pathology*; D008545:Melanoma / Q000201:enzymology / Q000235:genetics / Q000276:immunology* / Q000473:pathology*; D008565:Membrane Proteins / Q000096:biosynthesis / Q000172:deficiency; D010641:Phenotype; D012697:Serine Endopeptidases / Q000096:biosynthesis / Q000172:deficiency; D014407:Tumor Cells, Cultured; D000099167:Fibroblast Activation Protein Alpha
D017077:Culture Media, Conditioned; D018819:Dipeptidyl Peptidase 4; D010450:Endopeptidases; D018093:Gelatinases; D006131:Growth Inhibitors; D007166:Immunosuppressive Agents; D008565:Membrane Proteins; D012697:Serine Endopeptidases; D000099167:Fibroblast Activation Protein Alpha